Literature DB >> 33245683

Extensive characterization of the composition and functional activities of five preparations of human platelet lysates for dedicated clinical uses.

Liling Delila1, Yu-Wen Wu1, Ouada Nebie1, Rifa Widyaningrum2, Ming-Li Chou1, David Devos3, Thierry Burnouf1,4,5,6,7.   

Abstract

Human platelet lysates (HPLs), rich in various growth factors and cell growth-promoting molecules, encompass a new range of blood products that are being used for regenerative medicine, cell therapies, and tissue engineering. Well-characterized dedicated preparations, tailor-made to best fit specific therapeutic applications, are needed for optimal clinical efficacy and safety. Here, five types of HPL were prepared from the same platelet concentrates and extensively characterized to determine and compare their proteins, growth factors, cytokines, biochemical profiles, thrombin-generating capacities, thrombin-associated proteolytic activities, phospholipid-associated procoagulant potential, contents of extracellular vesicles expressing phosphatidylserine and tissue factor, and antioxidative properties. Our results revealed that all five HPL preparations contained detectable supraphysiological levels, in the ca. 0.1 ~ 350-ng/ml range, of all growth factors assessed, except insulin-like growth factor-1 detected only in HPL containing plasma. There were significant differences observed among these HPLs in total protein content, fibrinogen, complement components C3 and C4, albumin, and immunoglobulin G, and, most importantly, in their functional coagulant and procoagulant activities and antioxidative capacities. Our data revealed that the biochemical and functional properties of HPL preparations greatly vary depending upon their mode of production, with potential impacts on the safety and efficacy for certain clinical indications. Modes of preparation of HPLs should be carefully designed, and the product properties carefully evaluated based on the intended therapeutic use to ensure optimal clinical outcomes.

Entities:  

Keywords:  Cell therapy; HPL; platelet lysate; regenerative medicine

Year:  2020        PMID: 33245683     DOI: 10.1080/09537104.2020.1849603

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  3 in total

1.  Viability and Functionality of Neonatal Porcine Islet-like Cell Clusters Bioprinted in Alginate-Based Bioinks.

Authors:  Sarah Duin; Shreya Bhandarkar; Susann Lehmann; Elisabeth Kemter; Eckhard Wolf; Michael Gelinsky; Barbara Ludwig; Anja Lode
Journal:  Biomedicines       Date:  2022-06-15

Review 2.  Can the administration of platelet lysates to the brain help treat neurological disorders?

Authors:  Ouada Nebie; Luc Buée; David Blum; Thierry Burnouf
Journal:  Cell Mol Life Sci       Date:  2022-06-24       Impact factor: 9.207

3.  Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment.

Authors:  Ouada Nebie; Kevin Carvalho; Lassina Barro; Liling Delila; Emilie Faivre; Ting-Yi Renn; Ming-Li Chou; Yu-Wen Wu; Ariunjargal Nyam-Erdene; Szu-Yi Chou; Luc Buée; Chaur-Jong Hu; Chih-Wei Peng; David Devos; David Blum; Thierry Burnouf
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.